Vitespen Terminated Phase 2 Trials for Renal Cell Adenocarcinoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00082459Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma
NCT01147536Immune Response Following Treatment of Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence